Skip to main content
SpringerLink
Log in

A Practical Guide to the Management of Hypertension in Renal Transplant Recipients

  • Disease Management
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Hypertension as well as hypotension can be harmful to a newly transplanted renal allograft. Elevated blood pressure is also a major risk factor for cardiovascular death, which is a frequent occurrence despite successful renal transplantation. Renal artery stenosis, immunosuppressive drugs, chronic rejection, retained native kidneys, and excessive extracellular fluid volume may all contribute to post-transplant hypertension. Antihypertensive agents are widely used in the management of post-transplant hypertension. Careful clinical judgement and knowledge of the pharmacology, pharmacodynamics, pharmacokinetics, adverse drug reaction profiles, potential contraindications, and drug-drug interactions of anti-hypertensive agents are important when therapy with antihypertensive drugs is initiated in renal transplant recipients. Since blood pressure elevation in any individual is determined by a large number of hormonal and neuronal systems, the effect of antihypertensive agents on the allograft should be considered a critical factor in the management of hypertension in renal transplant recipients. Most renal transplant recipients have other risk factors for premature cardiovascular death such as diabetes mellitus, hypercholesterolemia, insulin resistance, obesity, left ventricular hypertrophy and ischaemic heart disease. Initial antihypertensive therapy should be tailored individually according to the patient’s risk factors. A realistic therapeutic goal for blood pressure management in the initial postoperative state is a systolic blood pressure <160mm Hg and a diastolic blood pressure <90mm Hg with lower pressure targets becoming applicable late post-transplantation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. US Renal Data System: USRDS 1997 Annual Report. The National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Disease. Bethesda (MD), 1997

  2. Raine AE. Hypertension and ischaemic heart disease in renal transplant recipients. Nephrol Dial Transplant 1995; 10 Suppl. 1:95–100

    PubMed  Google Scholar 

  3. Braun WE, Marwick TH. Coronary artery disease in renal transplant recipients. Cleve Clin J Med 1994; 61: 370–85

    PubMed  CAS  Google Scholar 

  4. Kokado Y, Takahara S, Kameoka H, et al. Hypertension in renal transplant recipients and its effect on long-term renal allograft survival. Transplant Proc 1996; 28: 1600–2

    PubMed  CAS  Google Scholar 

  5. Cosio FG, Falkenhain ME, Pesavento TE, et al. Relationships between arterial hypertension and renal allograft survival in African-American patients. Am J Kidney Dis 1997; 29: 419–27

    PubMed  CAS  Google Scholar 

  6. Collins R, Peto R, Godwin J, et al. Blood pressure and coronary heart disease. Lancet 1990; 336: 370–1

    PubMed  CAS  Google Scholar 

  7. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Pt1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765–74

    PubMed  CAS  Google Scholar 

  8. Mammen NI, Chacko N, Ganesh G, et al. Aspects of hypertension in renal allograft recipients: a study of 1000 live renal transplants. Br J Urol 1993; 71: 256–8

    PubMed  CAS  Google Scholar 

  9. Tripathi K, Prakash J. Refractory hypertension in transplant recipients. Transplant Proc 1992; 24: 1790–0

    PubMed  CAS  Google Scholar 

  10. Curtis JJ. Hypertension following kidney transplantation. Am J Kidney Dis 1994; 23: 471–5

    PubMed  CAS  Google Scholar 

  11. Curtis JJ. Management of hypertension after transplantation. Kidney Int 1993; 43 Suppl.: S45–9

    CAS  Google Scholar 

  12. Textor SC, Canzanello VJ, Taler SJ, et al. Cyclosporine-induced hypertension after transplantation. Mayo Clin Proc 1994; 69: 1182–93

    PubMed  CAS  Google Scholar 

  13. Kaye D, Thompson J, Jennings G, et al. Cyclosporine therapy after cardiac transplantation causes hypertension and renal vasoconstriction without sympathetic activation. Circulation 1993; 88: 1101–9

    PubMed  CAS  Google Scholar 

  14. Textor SC. De novo hypertension after liver transplantation. Hypertension 1993; 22: 257–67

    PubMed  CAS  Google Scholar 

  15. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Pt2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827–38

    PubMed  CAS  Google Scholar 

  16. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Kidney Int 1998; 53: 217–22

    PubMed  CAS  Google Scholar 

  17. Bennett, WM, Porter GA. Cyclosporine-associated hypertension [editorial]. Am J Med 1988; 85: 131–3

    PubMed  CAS  Google Scholar 

  18. Charnick SB, Nedelman JR, Chang CT, et al. Description of blood pressure changes in patients beginning cyclosporin A therapy. Ther Drug Monit 1997; 19: 17–24

    PubMed  CAS  Google Scholar 

  19. Kutkuhn B, Hollenbeck M, Westhoff A, et al. Renin secretion and captopril stimulation in hypertensive renal transplant recipients. Urol Int 1994; 52: 82–6

    PubMed  CAS  Google Scholar 

  20. Bennett WM, Porter GA. Cyclosporine-associated hypertension [editorial]. Am JMed 1988; 85: 131–3

    CAS  Google Scholar 

  21. van den Dorpel MA, van den Meiracker AH, Lameris TW, et al. Cyclosporin A impairs the nocturnal blood pressure fall in renal transplant recipients. Hypertension 1996; 28: 304–7

    PubMed  Google Scholar 

  22. Kasiske BL, Guijarro C, Massy ZA, et al. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996; 7: 158–65

    PubMed  CAS  Google Scholar 

  23. Kasiske BL. Risk factors for cardiovascular disease after renal transplantation. Miner Electrolyte Metab 1993; 19: 186–95

    PubMed  CAS  Google Scholar 

  24. Fervenza FC, Lafayette RA, Alfrey EJ, et al. Renal artery stenosis in kidney transplants. Am J Kidney Dis 1998; 31: 142–8

    PubMed  CAS  Google Scholar 

  25. Curtis JJ, Luke RG, Whelchel JD, et al. Inhibition of angiotensin-converting enzyme in renal-transplant recipients with hypertension. N Engl J Med 1983; 308: 377–81

    PubMed  CAS  Google Scholar 

  26. Kuo PC, Petersen J, Semba C, et al. CO2 angiography: a technique for vascular imaging in renal allograft dysfunction. Transplantation 1996; 61: 652–4

    PubMed  CAS  Google Scholar 

  27. Crook ED. The role of hypertension, obesity, and diabetes in causing renal vascular disease. Am J Med Sci 1999; 317: 183–8

    PubMed  CAS  Google Scholar 

  28. Mathur VS, Kerlan RK, Melzer J, et al. Acute renal allograft dysfunction secondary to suprarenal arterial stenosis: a case series and review of the literature. Clin Transplant 1998; 12: 333–42

    PubMed  CAS  Google Scholar 

  29. Wong W, Fynn SP, Higgins RM, et al. Transplant renal artery stenosis in 77 patients: does it have an immunological cause? Transplantation 1996; 61: 215–9

    PubMed  CAS  Google Scholar 

  30. Curtis JJ, Luke RG, Diethelm AG, et al. Benefits of removal of native kidneys in hypertension after renal transplantation. Lancet 1985; 2: 739–42

    PubMed  CAS  Google Scholar 

  31. Thompson JF, Fletcher EW, Wood RF, et al. Control of hypertension after renal transplantation by embolisation of host kidneys. Lancet 1984; 2: 424–7

    PubMed  CAS  Google Scholar 

  32. Fricke L, Doehn C, Steinhoff J, et al. Treatment of post-transplant hypertension by laparoscopic bilateral nephrectomy? Transplantation 1998; 65: 1182–7

    PubMed  CAS  Google Scholar 

  33. Teixeira MC, Mazucchi E, Nahas WC, et al. Peripheral renin activity predicts blood pressure control after bilateral nephrectomy in renal transplant patients. Transplant Proc 1997; 29: 220–1

    PubMed  CAS  Google Scholar 

  34. Szabo A, Patschan O, Kuttler B, et al. Hypertension accelerates the pace of chronic graft dysfunction in the rat. Transplant Int 1998; 11 Suppl. 1: S10–4

    Google Scholar 

  35. Kirkman RL, Strom TB, Weir MR, et al. Late mortality and morbidity in recipients of long-term renal allografts. Transplantation 1982; 34: 347–51

    PubMed  CAS  Google Scholar 

  36. Benediktsson H, Chea R, Davidoff A, et al. Antihypertensive drug treatment in chronic renal allograft rejection in the rat: effect on structure and function. Transplantation 1996; 62: 1634–42

    PubMed  CAS  Google Scholar 

  37. First MR, Neylan JF, Rocher LL, et al. Hypertension after renal transplantation. J Am Soc Nephrol 1994; 4: Suppl.: S30–6

    PubMed  CAS  Google Scholar 

  38. Schachter M. Cyclosporine A and hypertension. J Hypertens 1988; 6: 511–6

    PubMed  CAS  Google Scholar 

  39. Roullet JB, Xue H, Burdman EA, et al. Cardiovascular consequences of immunosuppressive drug treatment: a comparative study of cyclosporine A and cyclosporine G. Transplant Proc 1995; 27: 346–7

    PubMed  CAS  Google Scholar 

  40. Sudhir K, MacGregor JS, DeMarco T, et al. Cyclosporine impairs release of endothelium-derived relaxing factors in epicardial and resistance coronary arteries. Circulation 1994; 90: 3018–23

    PubMed  CAS  Google Scholar 

  41. Lee DB. Cyclosporine and the renin-angiotensin axis. Kidney Int 1997; 52: 248–60

    PubMed  CAS  Google Scholar 

  42. Elzinga LW, Rosen S, Bennet WM. Dissociation of glomerular filtration rate from the tubulointerstitial fibrosis in experimental chronic cyclosporine neprhopathy: role of sodium intake. J Am Soc Nephrol 1993; 4: 214–21

    PubMed  CAS  Google Scholar 

  43. Sander M, Lyson T, Thomas GD, et al. Sympathetic neural mechanisms of cyclosporine-induced hypertension. Am J Hypertens 1996; 9: 121–38S

    Google Scholar 

  44. Carvalho MJ, van den Meiracker AH, Boomsa F, et al. Role of sympathetic nervous system in cyclosporine-induced rise in blood pressure. Hypertension 1999; 34: 102–6

    PubMed  CAS  Google Scholar 

  45. de Mattos AM, Olyaei AJ, Bennett WM. Pharmacology of immunosuppressive medications used in renal diseases and transplantation. Am J Kidney Dis 1996; 28: 631–67

    PubMed  Google Scholar 

  46. Macleod AM, Thomson AW. FK 506: an immunosuppressant for the 1990s? Lancet 1991; 337: 25–7

    PubMed  CAS  Google Scholar 

  47. Whitworth JA. Studies on the mechanisms of glucocorticoid hypertension in humans. Blood Press 1994; 3: 24–32

    PubMed  CAS  Google Scholar 

  48. Whitworth JA. Mechanisms of glucocorticoid-induced hypertension. Kidney Int 1987; 31: 1213–24

    PubMed  CAS  Google Scholar 

  49. Schalekamp MA, Wenting GJ, Man in’t Veld AJ. Pathogenesis of mineralocorticoid hypertension. Clin Endocrinol Metab 1981; 10: 397–418

    PubMed  CAS  Google Scholar 

  50. Kuhlmann D, Ragan C, Ferrebee JW, et al. Toxic effects of desoxycorticosterone esters in dogs. Science 1939; 90: 496–7

    PubMed  CAS  Google Scholar 

  51. Mantero F, Armanini D, Boscaro M, et al. Steroids and hypertension. J Steroid Biochem Mol Biol 1991; 40: 35–44

    PubMed  CAS  Google Scholar 

  52. Grunfeld JP. Glucocorticoids in blood pressure regulation. Horm Res 1990; 34: 111–3

    PubMed  CAS  Google Scholar 

  53. Abdelhamid S, Muller-Lobeck H, Pahl S, et al. Prevalence of adrenal and extra-adrenal Conn syndrome in hypertensive patients. Arch Int Med 1996; 156: 1190–5

    CAS  Google Scholar 

  54. Saruta T. Mechanism of glucocorticoid-induced hypertension. Hypertens Res 1996; 19: 1–8

    PubMed  CAS  Google Scholar 

  55. Whitworth JA, Butkus A, Coghlan JP, et al. 9-alpha-Fluorocortisol-induced hypertension: a review. J Hypertens 1986; 4: 133–9

    PubMed  CAS  Google Scholar 

  56. Schulak JA, Hricik DE. Steroid withdrawal after renal transplantation. Clin Transplant 1994; 8 (Pt 2): 211–6

    PubMed  CAS  Google Scholar 

  57. Hricik DE, Lautman J, Bartucci MR, et al. Variable effects of steroid withdrawal on blood pressure reduction in cyclosporine-treated renal transplant recipients. Transplantation 1992; 53: 1232–5

    PubMed  CAS  Google Scholar 

  58. Pirsch JD, Armbrust MJ, Knechtle SJ, et al. Effect of steroid withdrawal on hypertension and cholesterol levels in living related recipients. Transplant Proc 1991; 23 (Pt 2): 1363–4

    PubMed  CAS  Google Scholar 

  59. Hricik DE, Kupin WL, First MR. Steroid-free immunosuppression after renal transplantation. J Am Soc Nephrol 1994; 4: Suppl.: S10–6

    PubMed  CAS  Google Scholar 

  60. Lipkin GW, Tucker B, Giles M, et al. Ambulatory blood pressure and left ventricular mass in cyclosporin- and non-cyclosporin-treated renal transplant recipients. J Hypertens 1993; 11: 439–42

    PubMed  CAS  Google Scholar 

  61. Meyer MM. Post-transplant hypertension. In: Bennett WM, McCarron DA, editors. Pharmacology and management of hypertension. New York: Churchill Livingstone, 1994: 181–215

    Google Scholar 

  62. Taler SJ, Textor SC, Canzanello VJ, et al. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. Transplantation 1996; 62: 1588–92

    PubMed  CAS  Google Scholar 

  63. Moser M. Hypertension can be treated effectively without increasing the cost of care. J Hum Hypertens 1996; 10: Suppl. 2: 533–8

    PubMed  Google Scholar 

  64. Reams GP. Renal effects of antihypertensive drugs. In: Bennett WM, McCarron DA, editors. Pharmacology, pharmacology and management of hypertension. New York: Churchill Livingstone, 1994: 29–54

    Google Scholar 

  65. Aronoff GR, Berns JS, Brier ME, et al. Drug prescribing in renal failure: dosing guidelines for adults. American College of Physicians. 4th ed. Philadelphia (PA): American College of Physicians, 1999

    Google Scholar 

  66. Bia MJ, Tyler K. Evidence that calcium channel blockade prevents cyclosporine-induced exacerbation of renal ischemic injury. Transplantation 1991; 51: 293–5

    PubMed  CAS  Google Scholar 

  67. Dawidson I, Rooth P, Fisher D, et al. Verapamil ameliorates acute cyclosporine A (CsA) nephrotoxicity and improves immunosuppression after cadaver renal transplantation. Transplant Proc 1989; 21 (Pt 2): 1511–3

    PubMed  CAS  Google Scholar 

  68. Dawidson I, Rooth P, Fry WR, et al. Prevention of acute cyclosporine-induced renal blood flow inhibition and improved immunosuppression with verapamil. Transplantation 1989; 48: 575–80

    PubMed  CAS  Google Scholar 

  69. Dawidson I, Rooth P, Alway C, et al. Verapamil prevents post-transplant delayed function and cyclosporine A nephrotoxicity. Transplant Proc 1990; 22: 1379–80

    PubMed  CAS  Google Scholar 

  70. Dawidson I, Rooth P, Lu C, et al. Verapamil improves the outcome after cadaver renal transplantation. J Am Soc Nephrol 1991; 2: 983–90

    PubMed  CAS  Google Scholar 

  71. Martinez-Castelao A, Hueso M, Sanz V, et al. Treatment of hypertension after renal transplantation: long-term efficacy of verapamil, enalapril, and doxazosin. Kidney Int 1998; 68 Suppl.: S130–S134

    CAS  Google Scholar 

  72. Schrier RW, Arnold PE, Van Putten VJ, et al. Cellular calcium in ischemic acute renal failure: role of calcium entry blockers. Kidney Int 1987; 32: 313–21

    PubMed  CAS  Google Scholar 

  73. Bia MJ, Tyler KA. Effect of cyclosporine on renal ischemic injury. Transplantation 1987; 43: 800–4

    PubMed  CAS  Google Scholar 

  74. Wagner K, Albrecht S, Neumayer HH. Prevention of post-transplant acute tubular necrosis by the calcium antagonist diltiazem: a prospective randomized study. Am J Nephrol 1987; 7: 287–91

    PubMed  CAS  Google Scholar 

  75. Neumayer HH, Lopping A, Veiten M, et al. Effect of cyclosporine A on post-ischemic acute renal failure in conscious dogs: role of vasoactive renal hormones. Transplant Proc 1987; 19: 4035–40

    PubMed  CAS  Google Scholar 

  76. Lee DB. Cyclosporine and the renin-angiotensin axis. Kidney Int 1997; 52: 248–60

    PubMed  CAS  Google Scholar 

  77. Ruggenenti P, Perico N, Mosconi L, et al. Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney Int 1993; 43: 706–11

    PubMed  CAS  Google Scholar 

  78. Sorensen SS, Skovbon H, Eiskjaer H, et al. Effect of felodipine on renal haemodynamics and tubular sodium handling in cyclosporin-treated renal transplant recipients. Nephrol Dial Transplant 1992; 7: 69–78

    PubMed  CAS  Google Scholar 

  79. Duggan KA, Macdonald GJ, Charlesworth JA, et al. Verapamil prevents post-transplant oliguric renal failure. Clin Nephrol 1985; 24: 289–91

    PubMed  CAS  Google Scholar 

  80. Morales JM, Rodriguez-Paternina E, Araque A, et al. Long-term protective effect of a calcium antagonist on renal function in hypertensive renal transplant patients on cyclosporine therapy: a 5-year prospective randomized study. Transplant Proc 1994; 26: 2598–9

    PubMed  CAS  Google Scholar 

  81. Palmer BF, Dawidson I, Sagalowsky A, et al. Improved outcome of cadaveric renal transplantation due to calcium channel blockers. Transplantation 1991; 52: 640–5

    PubMed  CAS  Google Scholar 

  82. McMillen MA, Lewis T, Jaffe BM, et al. Verapamil inhibition of lymphocyte proliferation and function in vitro. J Surg Res 1985; 39: 76–80

    PubMed  CAS  Google Scholar 

  83. Birx DL, Berger M, Fleisher TA. The interference of T cell activation by calcium channel blocking agents. J Immunol 1984; 133: 2904–9

    PubMed  CAS  Google Scholar 

  84. Schlueter WA, Batlle DC. Renal effects of antihypertensive drugs. Drugs 1989; 37: 900–25

    PubMed  CAS  Google Scholar 

  85. Iabichella ML, Dell’Omo G, Melillo E, et al. Calcium channel blockers blunt postural cutaneous vasoconstriction in hypertensive patients. Hypertension 1997; 29: 751–6

    PubMed  CAS  Google Scholar 

  86. Furberg CD, Psaty BM, Meyer JV Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326–31

    PubMed  CAS  Google Scholar 

  87. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620–5

    PubMed  CAS  Google Scholar 

  88. Pesavento TE, Jones PA, Julian B A, et al. Amlodipine increases cyclosporine levels in hypertensive renal transplant patients: results of a prospective study. J Am Soc Nephrol 1996; 7: 831–5

    PubMed  CAS  Google Scholar 

  89. Guan D, Wang R, Lu J, et al. Effects of nicardipine on blood cyclosporine levels in renal transplant patients. Transplant Proc 1996; 28: 1311–2

    PubMed  CAS  Google Scholar 

  90. Nadelmann J, Frishman WH. Clinical use of beta-adrenoceptor blockade in systemic hypertension. Drugs 1990; 39: 862–76

    PubMed  CAS  Google Scholar 

  91. Huysmans FT, van Heusden FH, Wetzels JF, et al. Antihypertensive effect of beta blockade in renal transplant recipients with or withouthost kidneys. Transplantation 1988;46: 234–7

    PubMed  CAS  Google Scholar 

  92. Hausberg M, Barenbrock M, Hohage H, et al. ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients. Hypertension 1999; 33: 862–8

    PubMed  Google Scholar 

  93. Wikstrand J. Primary prevention in patients with hypertension: comments on the clinical implications of the MAPHY Study. Metoprolol Atherosclerosis Prevention in Hypertensives Study. Am Heart J 1988; 116 (Pt 2): 338–47

    PubMed  CAS  Google Scholar 

  94. Kaplan NM. Critical comments on recent literature. SCRAAPHY about MAPHY from HAPPHY Am J Hypertens 1988; 1 (Pt 1): 428–30

    CAS  Google Scholar 

  95. Ritz E, Orth SR, Strzelczyk P. Angiotensin converting enzyme inhibitors, calcium channel blockers, and their combination in the treatment of glomerular disease. J Hypertens 1997; 15 Suppl.: S21–6

    CAS  Google Scholar 

  96. Moser M. Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists and calcium channel blocking agents: a review of potential benefits and possible adverse reactions. J Am Coll Cardiol 1997; 29: 1414–21

    PubMed  CAS  Google Scholar 

  97. Shusterman NH. Safety and efficacy of eprosartan, a new angiotensin II receptor blocker. Am Heart J 1999; 138: 238–45

    PubMed  CAS  Google Scholar 

  98. Traindl O, Falger S, Reading S, et al. The effects of lisinopril on renal function in proteinuric renal transplant recipients. Transplantation 1993; 55: 1309–13

    PubMed  CAS  Google Scholar 

  99. Bergman SM, Curtis JJ. Possible mediators in hypertension: renal factors. Semin Nephrol 1996; 16: 134–9

    PubMed  CAS  Google Scholar 

  100. Bochicchio T, Sandoval G, Ron O, et al. Fosinopril prevents hyperfiltration and decreases proteinuria in post-transplant hypertensives. Kidney Int 1990; 38: 873–9

    PubMed  CAS  Google Scholar 

  101. del Castillo D, Campistol JM, Guirado L, et al. Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. Kidney Int 1998; 68 Suppl.: S135–S139

    Google Scholar 

  102. Sennesael J, Lamote J, Violet I, et al. Comparison of perindopril and amlodipine in cyclosporine-treated renal allograft recipients. Hypertension 1995; 26: 436–44

    PubMed  CAS  Google Scholar 

  103. Mourad G, Ribstein J, Mimran A. Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants. Kidney Int 1993; 43: 419–25

    PubMed  CAS  Google Scholar 

  104. van der Schaaf MR, Hene RJ, Floor M, et al. Hypertension after renal transplantation: calcium channel or converting enzyme blockade? Hypertension 1995; 25: 77–81

    PubMed  Google Scholar 

  105. Sennesael JJ, Lamote JG, Violet I, et al. Divergent effects of calcium channel and angiotensin converting enzyme blockade on glomerulotubular function in cyclosporine-treated renal allograft recipients. Am J Kidney Dis 1996; 27: 701–8

    PubMed  CAS  Google Scholar 

  106. Grekas D, Dioudis C, Kalevrosoglou I, et al. Renal hemodynamics in hypertensive renal allograft recipients: effects of calcium antagonists and ACE inhibitors. Kidney Int 1996; 55 Suppl.: S97–100

    CAS  Google Scholar 

  107. Grekas D, Dioudis C, Kalevrosoglou I, et al. Management of moderate to severe hypertension and proteinuria by nifedipine retard and perindopril after renal transplantation. Clin Nephrol 1995; 44: 299–302

    PubMed  CAS  Google Scholar 

  108. Shihab FS, Bennett WM, Tanner AM, et al. Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine nephropathy. Kidney Int 1997; 52: 660–73

    PubMed  CAS  Google Scholar 

  109. De’Oliveira JM, Price DA, Fisher ND, et al. Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition. Kidney Int 1997; 52: 771–7

    PubMed  Google Scholar 

  110. Gaston RS, Julian BA, Curtis JJ. Post-transplant erythrocytosis: an enigma revisited. Am J Kidney Dis 1994; 24: 1–11

    PubMed  CAS  Google Scholar 

  111. Neutel JM. Metabolic manifestations of low-dose diuretics. Am J Med 1996; 101: 71S–82S

    PubMed  CAS  Google Scholar 

  112. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121: 289–300

    PubMed  CAS  Google Scholar 

  113. Swan SK. Diuretic strategies in patients with renal failure. Drugs 1994; 48: 380–5

    PubMed  CAS  Google Scholar 

  114. Ellison DH. The physiologic basis of diuretic synergism: its role in treating diuretic resistance. Ann Intern Med 1991; 114: 886–94

    PubMed  CAS  Google Scholar 

  115. Bittar AE, Ratcliffe PJ, Richardson AJ, et al. Hyperparathyroidism, hypertension and loop diuretic medication in renal transplant recipients. Nephrol Dial Transplant 1989; 4: 740–4

    PubMed  CAS  Google Scholar 

  116. Parfitt AM. The hyperparathyroidism of chronic renal failure: a disorder of growth. Kidney Int 1997; 52: 3–9

    PubMed  CAS  Google Scholar 

  117. West C, Carpenter BJ, Hakala TR. The incidence of gout in renal transplant recipients. Am J Kidney Dis 1987; 10: 369–72

    PubMed  CAS  Google Scholar 

  118. Hoes AW, Grobbee DE, Lubsen J, et al. Diuretics, beta-blockers, and the risk for sudden cardiac death in hypertensive patients Ann Intern Med 1995; 123: 481–7

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology, Hypertension and Clinical Pharmacology, Oregon Health Sciences University, 3314 SW US Veterans Hospital Road, Portland, Oregon, 97201, USA

    Ali J. Olyaei, Angelo M. deMattos &  William M. Bennett

Authors
  1. Ali J. Olyaei
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Angelo M. deMattos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. William M. Bennett
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William M. Bennett.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Olyaei, A.J., deMattos, A.M. & Bennett, W.M. A Practical Guide to the Management of Hypertension in Renal Transplant Recipients. Drugs 58, 1011–1027 (1999). https://doi.org/10.2165/00003495-199958060-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199958060-00005

Keywords

Search

Navigation